TCGA-50-5944-01A-11R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- PROTEIN_SECRETION+0.340
- TGF_BETA_SIGNALING+0.320
- ANDROGEN_RESPONSE+0.300
- MYOGENESIS+0.300
- BILE_ACID_METABOLISM+0.260
- HEDGEHOG_SIGNALING+0.250
- COAGULATION+0.240
- ANGIOGENESIS+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- E2F_TARGETS-0.570
- MYC_TARGETS_V1-0.520
- G2M_CHECKPOINT-0.480
- DNA_REPAIR-0.420
- OXIDATIVE_PHOSPHORYLATION-0.400
- MTORC1_SIGNALING-0.320
- TNFA_SIGNALING_VIA_NFKB-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 65f86d9a-828b-4e8b-a656-38baba5a54f7 | — | — | 0.889 |
| 2 | SRR10900010 | — | — | 0.872 |
| 3 | SRR8613790 | — | A | 0.868 |
| 4 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.864 |
| 5 | TCGA-CR-7389-01A-11R-2016-07 | — | — | 0.860 |
| 6 | SRR8518453 | — | F | 0.845 |
| 7 | BS_GV3NZ9QD | EPN | EPN Tumor | 0.845 |
| 8 | TCGA-BH-A0HP-01A-12R-A084-07 | — | A | 0.838 |
| 9 | TCGA-05-4405-01A-21R-1858-07 | — | cohortA1 | 0.835 |
| 10 | 8ee55a63-4e87-4c00-8012-4c87efdcb7ed | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |